Table 4.

Rituximab and autologous HCT

No. of rituximab
Author/reference
NHL histology
N
Mobilization
After HCT
Median follow-up, mo
Flinn11   Indolent   25   1   1   3  
Magni25   Indolent and mantle cell   15   4   2   10  
Ladetto26   Multiple   32   2-4   2   14  
Mangel27   Mantle cell   13   1   8*  8  
Rapoport28   Multiple (22 DLCL)   33   -   4   26  
Horwitz
 		 Multiple (25 DLCL)
 		 35
 		 -
 		 8†
 		 28
 
No. of rituximab
Author/reference
NHL histology
N
Mobilization
After HCT
Median follow-up, mo
Flinn11   Indolent   25   1   1   3  
Magni25   Indolent and mantle cell   15   4   2   10  
Ladetto26   Multiple   32   2-4   2   14  
Mangel27   Mantle cell   13   1   8*  8  
Rapoport28   Multiple (22 DLCL)   33   -   4   26  
Horwitz
 		 Multiple (25 DLCL)
 		 35
 		 -
 		 8†
 		 28
 
*

Variable schedule after HCT.

†

First 4 patients received only 4 doses.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal